Clinical development of anti-RANKL therapy

scientific article published in January 2007

Clinical development of anti-RANKL therapy is …
instance of (P31):
review articleQ7318358
scholarly articleQ13442814

External links are
P6179Dimensions Publication ID1020038270
P356DOI10.1186/AR2171
P8608Fatcat IDrelease_63abqnt2ovdztjcw6bbsngruyu
P932PMC publication ID1924522
P698PubMed publication ID17634146
P5875ResearchGate publication ID6204547

P50authorChristopher T RitchlinQ80623665
P2093author name stringEdward M Schwarz
P2860cites workOsteoprotegerin: a novel secreted protein involved in the regulation of bone densityQ24313918
TRANCE is a novel ligand of the tumor necrosis factor receptor family that activates c-Jun N-terminal kinase in T cellsQ24315251
Identification and characterization of a new member of the TNF family that induces apoptosisQ24318423
A homologue of the TNF receptor and its ligand enhance T-cell growth and dendritic-cell functionQ24336057
RANK is essential for osteoclast and lymph node developmentQ24598872
In vivo RANK signaling blockade using the receptor activator of NF-kappaB:Fc effectively prevents and ameliorates wear debris-induced osteolysis via osteoclast depletion without inhibiting osteogenesisQ28216662
Narrative [corrected] review: bisphosphonates and osteonecrosis of the jawsQ28240354
Denosumab in postmenopausal women with low bone mineral densityQ28298728
The long and the short of bone therapyQ28298737
OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph-node organogenesisQ28589430
Osteoclast differentiation and activationQ29547556
Clinical, biochemical, and radiographic effects of aminohydroxypropylidene bisphosphonate treatment in rheumatoid arthritisQ33561675
Antibody engineering via genetic engineering of the mouse: XenoMouse strains are a vehicle for the facile generation of therapeutic human monoclonal antibodiesQ33825182
Bisphosphonate-associated osteonecrosis of the jaw: the rheumatologist's roleQ35605709
Human antibodies from transgenic animalsQ36252986
Osteoprotegerin and RANKL regulate bone resorption, density, geometry and strengthQ36269835
Fully human therapeutic monoclonal antibodiesQ36347397
TRANCE, a tumor necrosis factor family member critical for CD40 ligand-independent T helper cell activationQ36368029
Chimeric anti-TNF-α monoclonal antibody cA2 binds recombinant transmembrane TNF-α and activates immune effector functionsQ41355139
The effect of a single dose of osteoprotegerin in postmenopausal womenQ43520860
A phase I study of AMGN-0007, a recombinant osteoprotegerin construct, in patients with multiple myeloma or breast carcinoma related bone metastasesQ44291815
Two year randomized controlled trial of etidronate in rheumatoid arthritis: changes in serum aminoterminal telopeptides correlate with radiographic progression of diseaseQ44334690
The effects of parathyroid hormone and alendronate alone or in combination in postmenopausal osteoporosisQ44590934
Regulatory effects of osteoprotegerin on cellular and humoral immune responsesQ44707640
OPG and PTH-(1-34) have additive effects on bone density and mechanical strength in osteopenic ovariectomized ratsQ46099755
A single-dose placebo-controlled study of AMG 162, a fully human monoclonal antibody to RANKL, in postmenopausal womenQ46133598
Alterations in canine vertebral bone turnover, microdamage accumulation, and biomechanical properties following 1-year treatment with clinical treatment doses of risedronate or alendronate.Q46281657
Tumor necrosis factor prevents alendronate-induced osteoclast apoptosis in vivo by stimulating Bcl-xL expression through Ets-2.Q46687366
A study of the biological receptor activator of nuclear factor-kappaB ligand inhibitor, denosumab, in patients with multiple myeloma or bone metastases from breast cancerQ46952812
Effects of receptor activator of NFkappaB (RANK) signaling blockade on fracture healingQ47846447
RANK signaling is not required for TNFalpha-mediated increase in CD11(hi) osteoclast precursors but is essential for mature osteoclast formation in TNFalpha-mediated inflammatory arthritis.Q51032592
Bisphosphonates suppress periosteal osteoblast activity independently of resorption in rat femur and tibia.Q51797992
Increased bone mass with pamidronate treatment in rheumatoid arthritis. Results of a three-year randomized, double-blind trialQ71016803
Double blind radiological assessment of continuous oral pamidronic acid in patients with rheumatoid arthritisQ72201830
Osteonecrosis of the jaw: more research neededQ80331532
P921main subjectpeptideQ172847
pharmaceutical scienceQ7180763
biomedical investigative techniqueQ66648976
P304page(s)S7
P577publication date2007-01-01
P1433published inArthritis Research and TherapyQ15757229
P1476titleClinical development of anti-RANKL therapy
P478volume9 Suppl 1

Reverse relations

cites work (P2860)
Q42659386A bone-resorption surface-targeting nanoparticle to deliver anti-miR214 for osteoporosis therapy
Q38175846A multi-targeted approach to treating bone metastases.
Q82871104A novel role for the marrow microenvironment in initiating and sustaining hematopoietic disease
Q39751683Advantages of bioluminescence imaging to follow siRNA or chemotherapeutic treatments in osteosarcoma preclinical models
Q37821350Androgen deprivation and bone
Q37354121Aromatase inhibitor-associated bone loss: clinical considerations
Q34111621Bone Health in Nonmetastatic Prostate Cancer: What’s the Big Deal?
Q92152784Bone Marrow-Derived Mesenchymal Stromal Cells: A Novel Target to Optimize Hematopoietic Stem Cell Transplantation Protocols in Hematological Malignancies and Rare Genetic Disorders
Q33754036Bone health in the prostate cancer patient receiving androgen deprivation therapy: a review of present and future management options
Q40231039Calreticulin inhibits inflammation-induced osteoclastogenesis and bone resorption
Q43205303Cancer pain physiology
Q51730575Cell-based glycan arrays for probing glycan-glycan binding protein interactions.
Q37029680Cervical actinomycosis with spinal cord compression. Case report and literature review
Q35003674Clinical significance of interleukin (IL)-6 in cancer metastasis to bone: potential of anti-IL-6 therapies
Q34960778Contemporary therapeutic approaches targeting bone complications in prostate cancer
Q36890431Current and emerging therapies for the treatment of osteoporosis
Q37152851Current state and future of joint replacements in the hip and knee
Q37342578Differential effects of biologic versus bisphosphonate inhibition of wear debris-induced osteolysis assessed by longitudinal micro-CT.
Q35622970Effect of bisphosphonates on orthodontic tooth movement-an update
Q34162783Effects of antiresorptive agents on osteomyelitis: novel insights into the pathogenesis of osteonecrosis of the jaw.
Q37658767Emerging therapeutic targets in breast cancer bone metastasis
Q37230477Emerging treatments for postmenopausal osteoporosis - focus on denosumab
Q35844745Glucocorticoid use in acute lymphoblastic leukaemia
Q34482369High affinity humanized antibodies without making hybridomas; immunization paired with mammalian cell display and in vitro somatic hypermutation
Q38944092Hormonal Modulation of Dendritic Cells Differentiation, Maturation and Function: Implications for the Initiation and Progress of Systemic Autoimmunity.
Q34991655Innovations in chemotherapy and radiation therapy: Implications and opportunities for the Asia-Pacific Rim.
Q36952052Integrated cellular bone homeostasis model for denosumab pharmacodynamics in multiple myeloma patients
Q81344046Is denosumab a safe and effective treatment for postmenopausal osteoporosis?
Q33862655Local application of osteoprotegerin-chitosan gel in critical-sized defects in a rabbit model
Q35310572Microarray and proteomic analysis of breast cancer cell and osteoblast co-cultures: role of osteoblast matrix metalloproteinase (MMP)-13 in bone metastasis
Q36823728Mouse anti-RANKL antibody delays oral wound healing and increases TRAP-positive mononuclear cells in bone marrow
Q33953955Multiple myeloma and bone disease: pathogenesis and current therapeutic approaches.
Q38616755New management options for osteoporosis with emphasis on SERMs
Q38209656Novel agents in the management of castration resistant prostate cancer.
Q37720488Novel approaches in the pharmacotherapy of skeletal-related events in metastatic castrate-resistant prostate cancer.
Q33642278Novel targeted therapeutics for metastatic castration-resistant prostate cancer.
Q38845640Osteocytic signalling pathways as therapeutic targets for bone fragility
Q38206487Osteoprotegerin and kidney disease
Q37011060Painful boney metastases
Q37187646Pathobiology and management of prostate cancer-induced bone pain: recent insights and future treatments.
Q39170948Proline/arginine-rich end leucine-rich repeat protein N-terminus is a novel osteoclast antagonist that counteracts bone loss
Q33757791Prostate cancer and bone: the elective affinities.
Q27009529Review of periprosthetic osteolysis in total joint arthroplasty: an emphasis on host factors and future directions
Q37571986Role of denosumab in breast cancer
Q33900327Safety concern between autologous fat graft, mesenchymal stem cell and osteosarcoma recurrence
Q34634763Targeted therapy in prostate cancer
Q27687098Targeting dendritic cell function during systemic autoimmunity to restore tolerance
Q34108110The emerging field of osteoimmunology
Q37825905Therapeutic targeting of osteoclast function and pathways.
Q34441944Treatment and prevention of bone complications from prostate cancer
Q82908399[Physiopathology, diagnosis and management of bone metastases from prostate cancer]